115 related articles for article (PubMed ID: 12372522)
21. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
22. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
[TBL] [Abstract][Full Text] [Related]
23. Lck is involved in interleukin-2 induced proliferation but not cell survival in human T cells through a MAP kinase-independent pathway.
Brockdorff J; Nielsen M; Kaltoft K; Mustelin T; Röpke C; Svejaard A; Geisler C; Odum N
Eur Cytokine Netw; 2000 Jun; 11(2):225-31. PubMed ID: 10903801
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of antitumor dendritic imides.
Braña MF; Domínguez G; Sáez B; Romerdahl C; Robinson S; Barlozzari T
Bioorg Med Chem Lett; 2001 Dec; 11(23):3027-9. PubMed ID: 11714603
[TBL] [Abstract][Full Text] [Related]
25. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
26. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
[TBL] [Abstract][Full Text] [Related]
27. SVM model for virtual screening of Lck inhibitors.
Liew CY; Ma XH; Liu X; Yap CW
J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors.
Rong F; Chow S; Yan S; Larson G; Hong Z; Wu J
Bioorg Med Chem Lett; 2007 Mar; 17(6):1663-6. PubMed ID: 17258458
[TBL] [Abstract][Full Text] [Related]
29. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.
Yorgin PD; Hartson SD; Fellah AM; Scroggins BT; Huang W; Katsanis E; Couchman JM; Matts RL; Whitesell L
J Immunol; 2000 Mar; 164(6):2915-23. PubMed ID: 10706677
[TBL] [Abstract][Full Text] [Related]
30. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
31. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
[TBL] [Abstract][Full Text] [Related]
32. A QSAR study on a series of pyrrole derivatives acting as lymphocyte-specific kinase (Lck) inhibitors.
Anwer Z; Gupta SP
Med Chem; 2012 Jul; 8(4):649-55. PubMed ID: 22548340
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain.
Hobbs CJ; Bit RA; Cansfield AD; Harris B; Hill CH; Hilyard KL; Kilford IR; Kitas E; Kroehn A; Lovell P; Pole D; Rugman P; Sherborne BS; Smith IE; Vesey DR; Walmsley DL; Whittaker D; Williams G; Wilson F; Banner D; Surgenor A; Borkakoti N
Bioorg Med Chem Lett; 2002 May; 12(10):1365-9. PubMed ID: 11992778
[TBL] [Abstract][Full Text] [Related]
34. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.
Elkamhawy A; Ali EMH; Lee K
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1574-1602. PubMed ID: 34233563
[TBL] [Abstract][Full Text] [Related]
35. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.
Gazit A; App H; McMahon G; Chen J; Levitzki A; Bohmer FD
J Med Chem; 1996 May; 39(11):2170-7. PubMed ID: 8667360
[TBL] [Abstract][Full Text] [Related]
36. The development of novel and selective p56lck tyrosine kinase inhibitors.
Bullington JL; Cameron JC; Davis JE; Dodd JH; Harris CA; Henry JR; Pellegrino-Gensey JL; Rupert KC; Siekierka JJ
Bioorg Med Chem Lett; 1998 Sep; 8(18):2489-94. PubMed ID: 9873567
[TBL] [Abstract][Full Text] [Related]
37. Ezrin is a substrate for Lck in T cells.
Autero M; Heiska L; Rönnstrand L; Vaheri A; Gahmberg CG; Carpén O
FEBS Lett; 2003 Jan; 535(1-3):82-6. PubMed ID: 12560083
[TBL] [Abstract][Full Text] [Related]
38. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
Bamborough P; Angell RM; Bhamra I; Brown D; Bull J; Christopher JA; Cooper AW; Fazal LH; Giordano I; Hind L; Patel VK; Ranshaw LE; Sims MJ; Skone PA; Smith KJ; Vickerstaff E; Washington M
Bioorg Med Chem Lett; 2007 Aug; 17(15):4363-8. PubMed ID: 17600705
[TBL] [Abstract][Full Text] [Related]
39. The protein tyrosine kinase p56(lck) regulates the serine-base exchange activity in Jurkat T cells.
Marhaba R; Dumaurier MJ; Pelassy C; Batoz M; Peyron JF; Breittmayer JP; Aussel C
FEBS Lett; 1997 Mar; 405(2):163-6. PubMed ID: 9089283
[TBL] [Abstract][Full Text] [Related]
40. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
